Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine

References

• Mach O, Tangermann RH, Wassilak SG, et al. Outbreaks of paralytic poliomyelitis during 1996-2012: the changing epidemiology of a disease in the final stages of eradication. J Infect Dis. 2014;210(Suppl 1):S275–S282.
   PubMedGoogle Scholar
• Duintjer Tebbens RJ, Thompson KM. Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers. Vaccine. 2017;35(31):3823–3833.
   PubMed Web of Science ®Google Scholar
• Sutter RW, Kew OM, Cochi SL, et al. Poliovirus vaccine – live. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Philadelphia: Saunders Elsevier; 2013. p. 598–645.
   Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006;26(6):1471–1505.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for OPV cessation. Expert Reviews of Vaccines. 2012;11(4):449–459.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation, and the end game of global polio eradication. Expert Rev Vaccines. 2014;13(2):221–234.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Poliovirus vaccination during the endgame: insights from integrated modeling. Expert Rev Vaccines. 2017;16(6):577–586.
   PubMed Web of Science ®Google Scholar
• Platt LR, Estivariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014;210(Suppl1):S380–389.
   PubMedGoogle Scholar
• Kew OM, Sutter RW, de Gourville EM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587–635.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, J-H K, et al. Review: oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal. 2013;23(4):680–702.
   Google Scholar
• Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science (80-). 2002;296(5566):356–359.
   PubMed Web of Science ®Google Scholar
• Wassilak SGF, Pate MA, Wannemuehler K, et al. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J Infect Dis. 2011;203(7):898–909.
   PubMed Web of Science ®Google Scholar
• World Health Assembly. Poliomyelitis: mechanism for management of potential risks to eradication (resolution 61.1). Geneva: World Health Organization; 2008.
   Google Scholar
• Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in two high-risk areas in northern India. J Infect Dis. 2014;210(Suppl 1):S398–S411.
   PubMedGoogle Scholar
• Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. J Infect Dis. 2014;210(Suppl 1):S412–S423.
   Google Scholar
• Global Polio Eradication Initiative. Global eradication of wild poliovirus type 2 declared. 2015. [cited 2015 Nov 30]. Available from: http://www.polioeradication.org/mediaroom/newsstories/Global-eradication-of-wild-poliovirus-type-2-declared/tabid/526/news/1289/Default.aspx
   Google Scholar
• Hampton LM, Farrell M, Ramirez-Gonzalez A, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - worldwide, 2016. Morbidity Mortality Weekly Report. 2016;65(35):934–938.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation. BMC Infect Dis. 2016;16:237.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, et al. Expert review on poliovirus immunity and transmission. Risk Anal. 2013;33(4):544–605.
   PubMed Web of Science ®Google Scholar
• Lapinleimu K. Elimination of poliomyelitis in Finland. Rev Infect Dis. 1984;6(Suppl 2):S457–S460.
   PubMedGoogle Scholar
• Oostvogel P, van Wijngaarden J, Hg VDA, et al. Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-3. The Lancet. 1994;344(8923):665–670.
   PubMed Web of Science ®Google Scholar
• Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. J Am Med Assoc. 2004;292(14):1696–1701.
   PubMed Web of Science ®Google Scholar
• Marine WM, Chin TD, Gravelle CR. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic. Am J Hyg. 1962;76:173–195.
   PubMed Web of Science ®Google Scholar
• Anis E, Kopel E, Singer S, et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveill. 2013;18(38):pii=20586.
   PubMedGoogle Scholar
• Kalkowska DA, Duintjer Tebbens RJ, Grotto I, et al. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis. 2015;211(11):1800–1812.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis. 2014;210(Suppl1):S475–S484.
   PubMedGoogle Scholar
• Más Lago P, Bravo JR, Andrus JK, et al. Lesson from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bull World Health Organ. 1994;72(2):221–225.
   PubMed Web of Science ®Google Scholar
• Más Lago P, Gary HE Jr., Pérez LS, et al. Poliovirus detection in wastewater and stools following an immunization campaign in Havana. Cuba. Int J Epidemiol. 2003;32:772–777.
   PubMed Web of Science ®Google Scholar
• Dunn G, Klapsa D, Wilton T, et al. Years of poliovirus replication in an immunodeficient individual: impact on the global polio eradication initiative. PLoS Pathog. 2015;11(8):e1005114.
   PubMed Web of Science ®Google Scholar
• MacCallum FO Hypogammaglobulinaemia in the United Kingdom. VII. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia. Medical Research Council Special Report Series, 310, 72–85 (1971).
   PubMedGoogle Scholar
• Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. BMC Infect Dis. 2015;15:379.
   PubMed Web of Science ®Google Scholar
• Guo J, Bolivar-Wagers S, Srinivas N, et al. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine. 2015;33(10):1235–1242.
   PubMed Web of Science ®Google Scholar
• Macklin G, Liao Y, Takane M, et al. Prolonged excretion of poliovirus among individuals with primary immunodeficiency disorder: an analysis of the World Health Organization Registry. Front Immunol. 2017;8:1103.
   PubMed Web of Science ®Google Scholar
• Shaghaghi M, Soleyman-Jahi S, Abolhassani H, et al. New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data. Vaccine. 2018;36(13):1711–1719.
   PubMed Web of Science ®Google Scholar
• Shulman LM, Manor Y, Sofer D, et al. Neurovirulent vaccine-derived polioviruses in sewage from highly immune populations. PLoS One. 2006;1:e69.
   PubMed Web of Science ®Google Scholar
• Roivainen M, Blomqvist S, Al-Hello H, et al. Highly divergent neurovirulent vaccine-derived polioviruses of all three serotypes are recurrently detected in Finnish sewage. Euro Surveill. 2010;15(19):pii/19566.
   PubMedGoogle Scholar
• Duintjer Tebbens RJ, Zimmermann M, Pallansch MA, et al. Insights from a systematic search for information on designs, costs, and effectiveness of poliovirus environmental surveillance systems. Food Environ Virol. 2017;9(4):361–382.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential OPV cessation risk management strategy. Epidemiol Infect. 2017;145(2):217–226.
   PubMed Web of Science ®Google Scholar
• Duizer E, Ruijs WL, van der Weijden CP, et al. Response to a wild poliovirus type 2 (WPV2)-shedding event following accidental exposure to WPV2, the Netherlands, April 2017. Euro Surveill. 2017;22(21):pii=30542.
   PubMedGoogle Scholar
• Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infect Dis. 2015;15:389.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global polio eradication initiative: polio eradication and endgame strategic plan (2013-2018). Geneva; 2013. Available from: http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/PEESP_EN_US.pdf
   Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Uncertainty and sensitivity analysis of cost assumptions for global long-term poliovirus risk management. J Vaccines Vaccination. 2016;7(5):339.
   Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, et al. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. 2013;23(4):703–749.
   Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, et al. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infect Dis. 2016;16:137.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use. Med Decis Making Policy Pract. 2017;2:1–13.
   Google Scholar
• Duintjer Tebbens RJ, Hampton LM, Wassilak SGF, et al. Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation. J Vaccines Vaccination. 2016;7(5):340.
   PubMedGoogle Scholar
• Duintjer Tebbens RJ, Hampton LM, Thompson KM. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use. BMC Infect Dis. 2018;18:165.
   PubMed Web of Science ®Google Scholar
• Jorba J, Diop OM, Iber J, et al. Update on vaccine-derived polioviruses - worldwide, January 2016-June 2017. MMWR Morb Mortal Wkly Rep. 2017;66(43):1185–1191.
   PubMed Web of Science ®Google Scholar
• Etsano A, Damisa E, Shuaib F, et al. Environmental isolation of circulating vaccine-derived poliovirus after interruption of wild poliovirus transmission - Nigeria, 2016. Morbidity Mortality Weekly Report. 2016;65(30):770–773.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in undervaccinated subpopulations. Risk Anal. 2018 Jan 3. doi: 10.1111/risa.12962. [Epub ahead of print].
   PubMedGoogle Scholar
• World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2012 - conclusions and recommendations. Weekly Epidemiological Record. 2012;87(21):204–207.
   Google Scholar
• World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2016 - conclusions and recommendations. Weekly Epidemiological Record. 2016;91(21):266–284.
   PubMedGoogle Scholar
• Global Polio Eradication Initiative. Post-certification strategic plan: a risk mitigation strategy for a polio-free world. 2017. Available from: http://polioeradication.org/wp-content/uploads/2017/11/polio-post-certification-strategic-plan-draft-17112017.pdf
   Google Scholar
• World Health Organization. Polio this week as of 17 April 2018. 2018. Available from: http://polioeradication.org/polio-today/polio-now/this-week/
   Google Scholar
• World Health Organization. Circulating vaccine-derived poliovirus. 2018. Available from: http://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/
   Google Scholar
• Global Polio Eradication Initiative. Responding to a poliovirus event and outbreak – part 2: protocol for poliovirus type 2. 2017. Available from: http://polioeradication.org/wp-content/uploads/2017/05/POL-SOPs-Part-2-260517-.pdf
   Google Scholar
• Global Polio Eradication Initiative. Responding to a poliovirus event and outbreak – part 2: protocol for poliovirus type 2. 2016. Available from: http://www.polioeradication.org/Portals/0/Document/Resources/PolioEradicators/1a.PolioOutbreakGuideline201604part2.pdf
   Google Scholar
• Thompson KM, Duintjer Tebbens RJ, Pallansch MA. Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Analysis. 2006;26(6):1541–1556.
   Google Scholar
• Thompson KM, Duintjer Tebbens RJ. Lessons from globally-coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes. J Infect Dis. 2017;216(Suppl 1):S168–S175.
   PubMedGoogle Scholar
• Duintjer Tebbens RJ, Thompson KM. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs. BMC Infect Dis. 2015;15:390.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Thompson KM. The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management. Future Microbiology. 2016;11(12):1549–1561.
   PubMed Web of Science ®Google Scholar
• Dowdle WR, Hgam VDA, de Gourville EM, et al. Containment of polioviruses after eradication: characterizing risk to improve management. Risk Anal. 2006;26(6):1449–1469.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Kalkowska DA, Thompson KM. Poliovirus containment risks and their management. Future Virol. 2018. doi: 10.2217/fvl-2018-0079. In press.
   Web of Science ®Google Scholar
• World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2017 - conclusions and recommendations. Weekly Epidemiological Record. 2017;92(22):301–320.
   PubMedGoogle Scholar
• Poliovirus AM. Studies during the endgame of the polio eradication program. Jpn J Infect Dis. 2017;70(1):1–6.
   PubMed Web of Science ®Google Scholar
• World Health Assembly. Global eradication of poliomyelitis by the year 2000 (resolution 41.28). Geneva: World Health Organization; 1988.
   Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. Economic analysis of the global polio eradication initiative. Vaccine. 2011;29(2):334–343.
   Web of Science ®Google Scholar